BioPharma Credit

LN: BPCR

$1373.9m market cap

$1 last close

BioPharma Credit was incorporated in October 2016 in the UK and aims at generating predictable income for shareholders over the long term through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. This includes senior secured notes, royalty debt instruments and priority royalty tranches. BPCR may also invest in unsecured debt (up to 35% of gross assets) as well as credit-linked notes. It can also have an equity exposure of up to 15% of gross assets.

Investment summary

BioPharma Credit (BPCR) has announced it has entered (alongside the BioPharma V fund) two five-year senior secured loan agreements with a total commitment of US$85m over the next 12 months (of which US$52.5m will be drawn initially). The terms of both loans are broadly in line with previous deals with a high single-digit floating interest rate, a 2% upfront fee and certain make-whole/prepayment fees. We estimate that BPCR still has at least US$344m in uncommitted cash (after excluding the recently declared dividend of US$0.0175 per share), which it aims to deploy before the end of the year.

Share price graph
Price performance
%
1m
3m
12m
Actual (0.5) (3.4) (4.3)
Relative* (1.7) (6.2) (8.1)
52-week high/low US$1.1/US$1.0
*% relative to local index
Key management
Alexander Perfall VP, Investor Relations & Public Affairs

Content on BioPharma Credit

You may also be interested in…